Sailesh T Desai retires from Sun Pharma Board of Directors
Maharashtra: Through a recent BSE filing, Sun Pharma has informed that Sailesh Trambaklal Desai will retire from the Company’s Board of Directors, as he is completing his term as a Director on March 31, 2024.
“This is to inform that Mr. Sailesh Trambaklal Desai (DIN: 00005443) retires from the Board of Directors of the Company upon completion of his term as a Director on March 31, 2024,” the Company stated.
Sailesh T. Desai has more than 28 years of industrial experience, 18 of which have been in the pharmaceutical industry. Desai has extensive and comprehensive corporate affairs experience, being involved in the turnaround at Milmet prior to Sun Pharma’s acquisition, as well as in the early stages of the company’s growth. He holds a BSc degree from the University of Calcutta.
Read also: Sun Pharma to buy 16.33 percent stake in Surgimatix for over Rs 25 crore
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Read also: Sun Pharma gets Australian regulatory nod for acne vulgaris treatment Winlevi
